The incorporation of L-asparaginase and pegylated asparaginase into pediatric-inspired regimens has conferred a survival advantage in treatment of adults with acute lymphoblastic leukemia. Use of asparaginase products requires careful prevention, monitoring, and management of adverse effects including hypersensitivity, hepatotoxicity, pancreatitis, coagulopathy, and thrombosis. Currently, there is limited published literature to offer guidance on management of these toxicities. At the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, a standard of practice guideline was created to prevent and manage asparaginase-related adverse events. By sharing our long-term experience with asparaginase products and clinical management of asparaginase-induced toxicities, this article aims to improve patient safety and optimize treatment outcomes.
KiddJG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum – course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med1953; 98: 565–582.
2.
BroomeJD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects and properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med1963; 118: 99–120.
3.
DolowyWCHensenDCornetJ, et al.Toxic and antineoplastic effects if L-asparaginase: study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer1966; 19: 1813–1819.
4.
HillJMRobertsJLoebE, et al.L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA1967; 202: 882–888.
5.
KwonYMChungHSMoonC, et al.L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Rel2009; 139: 182–189.
DinndorfPAGootenbergJCohenMH, et al.FDA drug approval summary: pegaspargase (Oncaspar®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist2007; 12: 991–998.
11.
EmadiAZokaeeHSausvilleEA. Asparaginase in the treatment of non-ALL hematologic malignancies. Cancer Chemother Pharmacol2014; 73: 875–883.
12.
HaleyEEFischerGAWelchAD. The requirement for L-asparagine of mouse leukemia cells L5178Y in culture. Cancer Res1961; 21: 532–536.
13.
KrallASXuSGraeberTG, et al.Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun2016; 7: 11457.
14.
MullerHJBoosJ. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol1998; 28: 97–113.
15.
ZhangJFanJVennetiS, et al.Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell2014; 56: 205–218.
16.
EmadiALawJYStrovelET, et al.Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol2018; 81: 217–222.
17.
WillemsLJacqueNJacquelA, et al.Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood2013; 122: 3521–3532.
LomelinoCLAndringJTMcKennaR, et al.Asparaginase synthetase: function, structure, and role in disease. J Biol Chem2017; 292: 19952–19958.
20.
AslanianAMFletcherBSKilbergMS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J2001; 357(Pt 1): 321–328.
21.
AvramisVISencerSPericlouAP, et al.A randomized comparison of Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: children's cancer group study. Blood2002; 99: 1986–1994.
22.
PanosyanEHSeibelNLMartin-AragonS, et al.Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children's cancer group study CCG-1961. J Pediatr Hematol Oncol2004; 26: 217–226.
23.
SallanSEGelberRDKimballV, et al.More is better! Update of Dana-Farber Cancer Institute/Children's Hospital Childhood acute lymphoblastic leukemia trials. Haematol Blood Transf1990; 33: 459–466.
24.
CurranEStockW. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood2015; 125: 3702–3710.
25.
SiegelSEAdvaniASeibelN, et al.Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol2018; 93: 1254–1266.
26.
SiegelSEStockWJohnsonRH, et al.Pediatric-inspired treatment regimens for adolescents and young adults with philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol2018; 4: 725–734.
27.
RyttingMEJabbourEJJorgensenJL, et al.Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol2016; 91: 819–823.
28.
Surveillance, epidemiology, and end results (SEER) cancer factsheets: acute lymphocytic Leukemia (ALL). Bethesda, MD: National Cancer Institute, (accessed 12 December 2018).
29.
StockWDouerDDeAngeloDJ, et al.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma2011; 52: 2237–2253.
30.
BoisselNSenderLS. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase. J Adolesc Young Adult Oncol2015; 4: 118–128.
31.
OettgenHFStephensonPASchwartzMK, et al.Toxicity of E. coli L-asparaginase in man. Cancer1970; 25: 253–278.
32.
HuguetFLeguayTRaffouxE, et al.Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol2009; 27: 911–918.
33.
DeAngeloDJStevensonKEDahlbergSE, et al.Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia2015; 29: 526–534.
34.
EttingerLJKurtzbergJVoutePA, et al.An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer1995; 75: 1176–1181.
35.
DouerDAldossILunningMA, et al.Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol2014; 32: 905–911.
36.
AsselinBL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol1999; 457: 621–629.
37.
KurtzbergJAsselinBPoplackD, et al.Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy [abstract]. Proc Annu Meet Am Assoc Cancer Res1993; 34: A1807.
38.
VroomanLMStevensonKESupkoJG, et al.Postinduction dexamethasone and individualized dosing of Escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study – Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol2013; 31: 1202–1210.
39.
StockWLugerSMAdvaniAS, et al.A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood2019. Epub ahead of print 18 January 2019.
40.
AhmedTHolwerdaSKlepinHD, et al.High dose cytarabine, mitoxantrone and L-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res2015; 39: 945–949.
41.
AdvaniAEarlMDouerD, et al.Toxicities of intravenous (IV) Pegasparaginase (ONCASPAR®) in adults with acute lymphoblastic leukemia (ALL). Blood2007; 110: 2811.
42.
DouerDYampolskyHCohenLJ, et al.Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood2007; 109: 2744–2750.
43.
WetzlerMSanfordBLKurtzbergJ, et al.Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood2007; 109: 4164–4167.
44.
AvramisVIPanosyanEH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present, and recommendations for the future. Clin Pharmacokinet2005; 44: 367–393.
45.
AdvaniASSanfordBLugerS, et al.Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance). Blood2013; 122: 3903.
46.
HoelzerDThielELofflerH, et al.Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood1984; 64: 38–47.
47.
PatelBKirkwoodAADeyA, et al.Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia2017; 31: 58–64.
48.
LarsonRAFretzinMHDodgeRK, et al.Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia1998; 12: 660–665.
49.
PetersenWCJrClarkDSennSL, et al.Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol2014; 31: 311–317.
50.
SilvermanLBStevensonKVroomanLM, et al.Randomized comparison of IV PEG and IM E. coli asparaginase in children and adolescents with acute lymphoblastic leukemia: results of the DFCI ALL Consortium Protocol 05-01. Blood2011; 118: 874.
51.
BurkeMJDevidasMMaloneyK, et al.Severe pegaspargase hypersensitivity reaction rates (grade ≥ 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma2018; 59: 1624–1633.
52.
ZhangPSunFLiuS, et al.Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Rel2016; 244(Pt B): 184–193.
53.
LongoNHardingCOBurtonBK, et al.Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicenter, phase 1 dose-escalation trial. Lancet2014; 384: 37–44.
54.
ArmstrongJKHempelGKolingS, et al.Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer2007; 110: 103–111.
Young DJ, Brown CJ, Arwood NM, et al. Universal premedication for asparaginase-based therapy should be standard of care. Poster presented at: American Society of Pediatric Hematology/Oncology; Pittsburgh, PA. 2–5 May 2018.
57.
SalzerWBostromBMessingerY, et al.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma2018; 59: 1797–1806.
58.
TongWHPietersRKaspersGJ, et al.A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood2014; 123: 2026–2033.
59.
van der SluisIMVroomanLMPietersR, et al.Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica2016; 101: 279–285.
60.
AsselinBL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol1999; 457: 621–629.
61.
AlachkarHFultonNSanfordB, et al.Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J2017; 17: 274–279.
62.
RoesmannAAfifyMPanseJ, et al.L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy2013; 59: 167–175.
63.
SahooSHartJ. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis2003; 23: 295–299.
64.
AldossIDouerDBehrendtCE, et al.Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol2016; 96: 375–380.
65.
RauschCRMariniBLBenitezLL, et al.PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia (†). Leuk Lymphoma2018; 59: 617–624.
66.
BurkePWAldossILunningMA, et al.Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res2018; 66: 49–56.
67.
BlackmanABoutinAShimanovskyA, et al.Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract2018; 24: 393–397.
68.
Al-NawakilCWillemsLMauprivezC, et al.Successful treatment of L-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymph2014; 55: 1670–1674.
69.
Alshiekh-NasanyRDouerD. L-carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol2016; 135: 208–210.
70.
LuGKarurVHerringtonJD, et al.Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine. Proc Bayl Univ Med Cent2016; 29: 46–47.
71.
KearneySLDahlbergSELevyDE, et al.Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer2009; 53: 162–167.
72.
TrivediCDPitchumoniCS. Drug-induced pancreatitis: an update. J Clin Gastroenterol2005; 39: 709–716.
73.
RajaRASchmiegelowKFrandsenTL. Asparaginase-associated pancreatitis in children. Br J Haematol2012; 159: 18–27.
74.
PiascikMRydzewskaGMilewskiJ, et al.The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas2010; 39: 863–867.
75.
GarringtonTBensardDIngramJD, et al.Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis. Med Pediatr Oncol1998; 30: 106–109.
76.
ParanHNeufeldDMayoA, et al.Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg1995; 181: 121–124.
77.
BuieLWMooreJvan DeventerH. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis. Pharmacotherapy2014; 34: e149–151.
78.
GoyalGBhattVR. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Future Oncol2015; 11: 2459–2470.
79.
AlbayrakMGurselTKayaZ, et al.Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia. Clin Appl Thromb Hemost2013; 19: 644–651.
80.
Hunault-BergerMChevallierPDelainM, et al.Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica2008; 93: 1488–1494.
81.
GraceRFDahlbergSENeubergD, et al.The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol2011; 152: 452–459.
82.
LiangJShiPGuoX, et al.A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncol Lett2018; 15: 75–82.
83.
WadaHThachilJDi NisioM, et al.Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost2013. 11: 761–767.
84.
SteinerMAttarbaschiAHaasOA, et al.Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy. Leukemia2008; 22: 1290.
85.
Nowak-GöttlURathBBinderM, et al.Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica1995; 80: 451–453.
86.
FranchiniMLippiG. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus2012; 10: 23–27.
87.
Kozek-LangeneckerSSørensenB, et al.Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care2011; 15: R239.
88.
OrvainCBalsatMLheritierV, et al.Prevention of venous thrombotic events in adult patients with acute lymphoblastic leukemia treated in a pediatric-inspired protocol – a Graall Study. Blood2016; 128: 2776.
89.
BolligerDSzlamFMolinaroRJ, et al.Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth2009; 102: 793–799.
90.
WalkerCPRoystonD. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth2002; 88: 848–863.
91.
Tollefsen DM. Chapter 176: Antithrombin Deficiency. In: D Valle, AL Beaudet, B Vogelstein, KW Kinzler, SE Antonarakis, A Ballabio, KM Gibson, G Mitchell (eds.) The Online Metabolic and Molecular Bases of Inherited Disease, 2000; New York, NY: McGraw-Hill; OMMBID. Web 12 December 2018.
92.
De StefanoVZaTCiminelloA, et al.Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost2015; 113: 247–261.
93.
CarusoVLacovielloLDi CastelnuovoA, et al.Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood2006; 108: 2216–2222.
94.
ElliottMAWolfRCHookCC. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma2004; 45: 1545–1549.
95.
ElhasidRLanirNSharonR, et al.Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coag Fibrinol2001; 12: 367–370.
96.
GraceRFDeAngeloDJStevensonKE, et al.The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis2018; 45: 306–314.
97.
SibaiHSekiJTWangTQ, et al.Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia. Curr Oncol2016; 23: e355–361.
98.
MitchellLAndrewMHannaK, et al.Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost2003; 90: 235–244.
99.
FarrellKFyfeAAllanJ, et al.An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leuk Lymphoma2016; 57: 2568–2574.
100.
ChenJNgoDAldossI, et al.Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia. Leuk Lymphoma. Epub ahead of print 15 October 2018.
101.
MeisterBKropshoferGKlein-FrankeA, et al.Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer2008; 50: 298–303.
LeeAYLevineMNBakerRI, et al.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med2003; 349: 146–153.
104.
ManthaSMiaoYWillsJ, et al.Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis2017; 43: 514–518.
105.
OliverNShortBTheinM. Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation. Leuk Lymphoma2015; 56: 2082–2086.
106.
RodgersGM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost2009; 101: 806–812.
BarretoJNMcCulloughKBPeskeyCS, et al.Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leuk Lymphoma2017; 58: 2588–2597.
109.
Thrombate III (Antithrombin III [Human]) [package insert]. Research Triangle Park: Grifols Therapeutics Inc., NC, 2016.
